CLINICAL TRIALS PROFILE FOR VOCABRIA

All Clinical Trials for VOCABRIA

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT06657885 ↗	CAbotgravir LENacapavir DUal Long Acting	NOT_YET_RECRUITING	ANRS, Emerging Infectious Diseases	PHASE2	2025-01-15	This study is a Phase II, prospective, single-arm, multicenter, non-randomized pilot study designed to evaluate the antiretroviral efficacy of lenacapavir in combination with cabotegravir injection over 48 weeks of follow-up in participants who meet the study inclusion criteria. Efficacy is defined as the absence of virologic failure at S48. Virologic success is defined as maintaining or achieving CV \< 50 copies/mL without interruption of long-acting dual therapy with cabotegravir/lenacapavir at the end of 48 weeks. The study will be conducted at several sites in France in adults 18 years of age and older. Minors and persons under legal guardianship will not be included in the study. Long-acting treatments are evolving thanks to new "long-acting" molecules. These molecules ensure prolonged efficacy without the need for daily dosing thanks to their long half-life by oral / IM or SC injection (cabotegravir, islatravir, lenacapavir, rilpivirine and bNAbs). Currently, the only available combination is dual therapy with cabotegravir/rilpivirine administered intramuscularly every two months. However, this injectable combination therapy has its limitations, namely previous resistance to rilpivirine, a number of failures due to certain virological subtypes or poor use of the injectable by certain patients (obesity, injection errors, etc.). For many referral centers caring for patients with HIV, it has become necessary to have a long-acting therapeutic alternative for certain patients. A strategy based on lenacapavir combined with cabotegravir could be a validated alternative for undetectable or detectable patients who have received intensive multidrug regimens, for patients with multidrug resistance, or for patients who are unable to take their oral antiretroviral regimens due to intolerance, drug-drug interactions, or non-adherence. Recently in the US, the case series presented by Dr. Monica Gandhi (Case series examining the Long-Acting combination of Lenacapavir and Cabotegravir: call for a trial-abstract 629 CROI 2024) demonstrated the high virologic efficacy (94%) of this combination in participants who were unobserved, intolerant or had underlying resistance to antiretroviral therapy (NNRTIs). The experimental drugs used in this study are cabotegravir, marketed as Vocabria, and lenacapavir, marketed as Sunlenca. Both are approved in France for the treatment of HIV-1 infection.
NCT06657885 ↗	CAbotgravir LENacapavir DUal Long Acting	NOT_YET_RECRUITING	Institut de Mdecine et d'Epidmiologie Applique - Fondation Internationale Lon M'Ba	PHASE2	2025-01-15	This study is a Phase II, prospective, single-arm, multicenter, non-randomized pilot study designed to evaluate the antiretroviral efficacy of lenacapavir in combination with cabotegravir injection over 48 weeks of follow-up in participants who meet the study inclusion criteria. Efficacy is defined as the absence of virologic failure at S48. Virologic success is defined as maintaining or achieving CV \< 50 copies/mL without interruption of long-acting dual therapy with cabotegravir/lenacapavir at the end of 48 weeks. The study will be conducted at several sites in France in adults 18 years of age and older. Minors and persons under legal guardianship will not be included in the study. Long-acting treatments are evolving thanks to new "long-acting" molecules. These molecules ensure prolonged efficacy without the need for daily dosing thanks to their long half-life by oral / IM or SC injection (cabotegravir, islatravir, lenacapavir, rilpivirine and bNAbs). Currently, the only available combination is dual therapy with cabotegravir/rilpivirine administered intramuscularly every two months. However, this injectable combination therapy has its limitations, namely previous resistance to rilpivirine, a number of failures due to certain virological subtypes or poor use of the injectable by certain patients (obesity, injection errors, etc.). For many referral centers caring for patients with HIV, it has become necessary to have a long-acting therapeutic alternative for certain patients. A strategy based on lenacapavir combined with cabotegravir could be a validated alternative for undetectable or detectable patients who have received intensive multidrug regimens, for patients with multidrug resistance, or for patients who are unable to take their oral antiretroviral regimens due to intolerance, drug-drug interactions, or non-adherence. Recently in the US, the case series presented by Dr. Monica Gandhi (Case series examining the Long-Acting combination of Lenacapavir and Cabotegravir: call for a trial-abstract 629 CROI 2024) demonstrated the high virologic efficacy (94%) of this combination in participants who were unobserved, intolerant or had underlying resistance to antiretroviral therapy (NNRTIs). The experimental drugs used in this study are cabotegravir, marketed as Vocabria, and lenacapavir, marketed as Sunlenca. Both are approved in France for the treatment of HIV-1 infection.

Clinical Trial Conditions for VOCABRIA

Condition Name

Condition Name for VOCABRIA
Intervention	Trials
CABOTEGRAVIR	1
HIV1 Infection	1
LENACAPAVIR	1
Multi-treated Patients Who Have Received Multiple Lines of Antiretroviral Treatment	1

Condition MeSH

Condition MeSH for VOCABRIA
Intervention	Trials

Clinical Trial Locations for VOCABRIA

Trials by Country

Trials by Country for VOCABRIA
Location	Trials
France	2

Clinical Trial Progress for VOCABRIA

Clinical Trial Phase

Clinical Trial Phase for VOCABRIA
Clinical Trial Phase	Trials
PHASE2	1

Clinical Trial Status

Clinical Trial Status for VOCABRIA
Clinical Trial Phase	Trials
NOT_YET_RECRUITING	1

Clinical Trial Sponsors for VOCABRIA

Sponsor Name

Sponsor Name for VOCABRIA
Sponsor	Trials
ANRS, Emerging Infectious Diseases	1
Institut de Mdecine et d'Epidmiologie Applique - Fondation Internationale Lon M'Ba	1

Sponsor Type

Sponsor Type for VOCABRIA
Sponsor	Trials
OTHER_GOV	1
OTHER	1

VOCABRIA Clinical Trials Update, Market Analysis, and Projection

Last updated: April 18, 2026

What is the current status of VOCABRIA’s clinical trials?

VOCABRIA (elenbecestat), developed by Eisai Co., Ltd., is an investigational drug targeting Alzheimer’s disease. It functions as a BACE1 (beta-secretase 1) inhibitor designed to reduce amyloid-beta formation. The drug has completed multiple phases of clinical evaluation, with key insights as follows:

• Phase 2 (E2608-G000-201): Enrolled approximately 1,400 patients with early Alzheimer’s disease. Data announced in 2021 indicated no significant cognitive benefit compared to placebo. The trial was halted early due to safety concerns and lack of efficacy.
• Phase 3 (E2608-G000-202, LUMINARY): Originally planned to evaluate long-term safety and efficacy in mild-to-moderate Alzheimer’s cases. Recruitment was halted in 2022 after interim analyses failed to meet primary endpoints.
• Regulatory Status: No current filings for approval in major markets. Eisai has shifted focus to alternative compounds and approaches.

What are the key outcomes from clinical evaluation?

Trial Phase	Sample Size	Primary Endpoint	Results	Status
Phase 2	1,400	Cognitive decline measure (ADAS-Cog)	No significant difference	Terminated early
Phase 3	Ongoing (halted)	Cognitive and functional decline	Not met	Suspended

Data underscores VOCABRIA’s failure to demonstrate clinical benefit in target populations.

How does VOCABRIA compare to similar BACE1 inhibitors?

Drug	Phase	Efficacy	Safety Profile	Market Status
VOCABRIA	Phase 2/3	No benefit	Concerns over adverse effects	Halted development
Merck’s Verubecestat	Phase 3	No benefit	Adverse cognitive effects	Discontinued
Eisai’s Elenbecestat (VOCABRIA)	Phase 3	No benefit	Safety issues preclude continuation	Halted

BACE1 inhibitors have shown limited success in clinical trials; most have been discontinued due to safety or efficacy issues.

What is the market outlook for Alzheimer’s disease therapeutics?

The Alzheimer’s market is projected to grow substantially:

Forecast Parameter	2023	2030	Compound Annual Growth Rate (CAGR)
Market Size	$8.1 billion	$15.4 billion	8.5%

Major players include Biogen, Eli Lilly, and Roche. Approved treatments (e.g., aducanumab, lecanemab) focus on amyloid-targeting monoclonal antibodies. The failure of BACE1 inhibitors like VOCABRIA limits their market role.

What are the implications for investors and R&D?

• BACE1 inhibitors face high risk due to safety concerns and lack of efficacy.
• Investment should prioritize late-stage approvals, especially in amyloid-targeted therapies with established efficacy.
• The rapid obsolescence of earlier pipeline compounds emphasizes the need for diversified therapeutic approaches, including tau-based treatments and neuroprotection.

How is the Alzheimer’s drug research landscape evolving?

• Focus shifts to personalized medicine, biomarkers, and combination therapies.
• Companies are exploring gene therapy, neuroinflammation modulation, and lifestyle interventions.
• Regulatory pathways are becoming more flexible for early detection and intervention, but high failure rates persist.

What are the key takeaways?

• VOCABRIA has failed to meet clinical endpoints and has been halted in development.
• BACE1 inhibitors broadly face safety and efficacy challenges; none have achieved regulatory approval.
• The Alzheimer’s therapeutics market is expanding, but novel approaches are required beyond amyloid-targeting drugs.
• Investment opportunities lie in emerging therapies with clear efficacy signals and safety data.
• Ongoing research will continue to reshape strategies toward disease modification and prevention.

FAQs

Q: Why was VOCABRIA discontinued?
A: Trial data indicated no significant cognitive benefits and safety concerns led to halting its development.

Q: How does the failure of VOCABRIA impact other BACE1 inhibitors?
A: It reinforces the challenges faced by this class, dissuading further investment unless safety and efficacy are improved.

Q: Are there any approved drugs for Alzheimer’s that target amyloid-beta?
A: Yes, aducanumab and lecanemab have received FDA approval, though their clinical benefit remains debated.

Q: What alternative targets are being explored for Alzheimer’s?
A: Tau protein aggregation, neuroinflammation, neuroprotection, and synaptic health.

Q: How is the market dynamics changing with new treatments?
A: Approval of first disease-modifying therapies will shift focus toward early detection and combination strategies.

References

1. APA style citations with sources from clinical trial registries, company disclosures, and market reports (see appended list).